A PYMNTS Company

EU: Danaher wins conditional EU okay for $21 billion biopharma buy

By  |  December 18, 2019

US medical equipment maker Danaher secured conditional EU approval on Wednesday for its $21.4 billion bid for General Electric’s biopharma business after agreeing to sell five businesses to address competition concerns.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Danaher unveiled the deal in February, which will boost its presence in the biopharma industry, giving it access to tools for research and development of drugs.

    The European Commission said Danaher will sell businesses in the United States, China, France and Britain after it voiced concerns that the deal would have reduced competition and pushed up prices of certain products in some markets.

    Full Content: Reuters

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.